Disease area
Hematologic malignancies
Multiple myeloma
B-cell malignancies
Myeloid malignancies
Classical hematology
Showing 3 recruiting clinical trials
Severe hemolytic disease of the fetus and newborn
AZALEA
Phase
NCT05912517
Compound
Nipocalimab-aahu (anti-FcRn mAb)
Fetal and neonatal alloimmune thrombocytopenia
FREESIA-1
Phase
NCT06449651
Compound
Nipocalimab-aahu (anti-FcRn mAb)
Fetal and neonatal alloimmune thrombocytopenia
FREESIA-3
Phase
NCT06533098
Compound
Nipocalimab-aahu (anti-FcRn mAb)
The safety and efficacy of the investigational use of these products have not been determined.
There is no guarantee that the investigational uses listed will be filed with and/or approved for marketing by any regulatory agency.
FcRn, neonatal crystallizable fragment receptor; mAb, monoclonal antibody.